Micro<scp>RNA</scp>‐661 modulates redox and metabolic homeostasis in colon cancer

Cedrón, Marta Gómez de; Pérez, Rebeca Acín; Martínez, Rubén; Molina, Susana; Herránz, Jesús; Feliú, Jaime; Reglero, Guillermo; Enríquez, José Antonio; Molina, Ana Ramı́rez de

doi:10.1002/1878-0261.12142

Cited by 18 publications

(10 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Here, our findings suggested that on miR-539 might be a tumor promoter in contrast to previous experimental studies. On the other hand, prior studies showed that miR-661 was a tumor promoter in non-small cell lung cancer, colon cancer and ovarian cancer [55][56][57]. However, the roles of miR-661 in HCC development has not been investigated.…”

Section: Plos Onementioning

confidence: 99%

Unveiling prognostics biomarkers of tyrosine metabolism reprogramming in liver cancer by cross-platform gene expression analyses

Nguyen¹,

Nguyen²,

Le³

2020

PLoS ONE

View full text Add to dashboard Cite

Tyrosine is mainly degraded in the liver by a series of enzymatic reactions. Abnormal expression of the tyrosine catabolic enzyme tyrosine aminotransferase (TAT) has been reported in patients with hepatocellular carcinoma (HCC). Despite this, aberration in tyrosine metabolism has not been investigated in cancer development. In this work, we conduct comprehensive cross-platform study to obtain foundation for discoveries of potential therapeutics and preventative biomarkers of HCC. We explore data from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), Gene Expression Profiling Interactive Analysis (GEPIA), Oncomine and Kaplan Meier plotter (KM plotter) and performed integrated analyses to evaluate the clinical significance and prognostic values of the tyrosine catabolic genes in HCC. We find that five tyrosine catabolic enzymes are downregulated in HCC compared to normal liver at mRNA and protein level. Moreover, low expression of these enzymes correlates with poorer survival in patients with HCC. Notably, we identify pathways and upstream regulators that might involve in tyrosine catabolic reprogramming and further drive HCC development. In total, our results underscore tyrosine metabolism alteration in HCC and lay foundation for incorporating these pathway components in therapeutics and preventative strategies.

show abstract

Section: Plos Onementioning

confidence: 99%

Unveiling prognostics biomarkers of tyrosine metabolism reprogramming in liver cancer by cross-platform gene expression analyses

Nguyen¹,

Nguyen²,

Le³

2020

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Dysregulated expression of multiple rate-limiting enzymes may lead to activation of the Warburg effect in cancer [7][8][9]. Previous evidence indicated that altered metabolic genes or miRNAs modulate metabolic homeostasis in CC [10][11][12]. Moreover, abnormal changes in this signaling pathway direct a metabolic program of glycolysis in CC [13].…”

Section: Introductionmentioning

confidence: 99%

A Novel Seventeen-Gene Metabolic Signature for Predicting Prognosis in Colon Cancer

Luo

Shan

Liu

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

A metabolic disorder is considered one of the hallmarks of cancer. Multiple differentially expressed metabolic genes have been identified in colon cancer (CC), and their biological functions and prognostic values have been well explored. The purpose of the present study was to establish a metabolic signature to optimize the prognostic prediction in CC. The related data were downloaded from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx) database, and Gene Expression Omnibus (GEO) combined with GSE39582 set, GSE17538 set, GSE33113 set, and GSE37892 set. The differentially expressed metabolic genes were selected for univariate Cox regression and lasso Cox regression analysis using TCGA and GTEx datasets. Finally, a seventeen-gene metabolic signature was developed to divide patients into a high-risk group and a low-risk group. Patients in the high-risk group presented poorer prognosis compared to the low-risk group in both TCGA and GEO datasets. Moreover, gene set enrichment analyses demonstrated multiple significantly enriched metabolism-related pathways. To sum up, our study described a novel seventeen-gene metabolic signature for prognostic prediction of colon cancer.

show abstract

“…Zhang et al [ 27 ] found that miR-206 induces ROS accumulation in vivo and in vitro by binding to SOD1 mRNA, which may be a cause of cardiovascular disease. Gómez de Cedrón et al [ 28 ] reported that miR-661 regulates redox and metabolic homeostasis in colon cancer. Therefore, it is noteworthy to reveal the multidimensional regulatory network in tumor genesis and progression of prognosis-related RRGs and miRNAs in this study.…”

Section: Resultsmentioning

confidence: 99%

Integrated Analysis to Identify a Redox‐Related Prognostic Signature for Clear Cell Renal Cell Carcinoma

Xian

Feng

et al. 2021

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

The imbalance of the redox system has been shown to be closely related to the occurrence and progression of many cancers. However, the biological function and clinical significance of redox-related genes (RRGs) in clear cell renal cell carcinoma (ccRCC) are unclear. In our current study, we downloaded transcriptome data from The Cancer Genome Atlas (TCGA) database of ccRCC patients and identified the differential expression of RRGs in tumor and normal kidney tissues. Then, we identified a total of 344 differentially expressed RRGs, including 234 upregulated and 110 downregulated RRGs. Fourteen prognosis-related RRGs (ADAM8, CGN, EIF4EBP1, FOXM1, G6PC, HAMP, HTR2C, ITIH4, LTB4R, MMP3, PLG, PRKCG, SAA1, and VWF) were selected out, and a prognosis-related signature was constructed based on these RRGs. Survival analysis showed that overall survival was lower in the high-risk group than in the low-risk group. The area under the receiver operating characteristic curve of the risk score signature was 0.728 at three years and 0.759 at five years in the TCGA cohort and 0.804 at three years and 0.829 at five years in the E-MTAB-1980 cohort, showing good predictive performance. In addition, we explored the regulatory relationships of these RRGs with upstream miRNA, their biological functions and molecular mechanisms, and their relationship with immune cell infiltration. We also established a nomogram based on these prognostic RRGs and performed internal and external validation in the TCGA and E-MTAB-1980 cohorts, respectively, showing an accurate prediction of ccRCC prognosis. Moreover, a stratified analysis showed a significant correlation between the prognostic signature and ccRCC progression.

show abstract

MicroRNA‐661 modulates redox and metabolic homeostasis in colon cancer

Cited by 18 publications

References 39 publications

Unveiling prognostics biomarkers of tyrosine metabolism reprogramming in liver cancer by cross-platform gene expression analyses

Unveiling prognostics biomarkers of tyrosine metabolism reprogramming in liver cancer by cross-platform gene expression analyses

A Novel Seventeen-Gene Metabolic Signature for Predicting Prognosis in Colon Cancer

Integrated Analysis to Identify a Redox‐Related Prognostic Signature for Clear Cell Renal Cell Carcinoma

Contact Info

Product

Resources

About